Cargando…
HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure
The success of many current vaccines relies on a formulation that incorporates an immune activating adjuvant. This will hold true for the design of a successful therapeutic HIV vaccine targeted at controlling reactivated virus following cessation of combined antiretroviral therapy (cART). The HIV ac...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594582/ https://www.ncbi.nlm.nih.gov/pubmed/28893294 http://dx.doi.org/10.1186/s12981-017-0175-6 |